Our Founders

EstryX Pharma Limited is a new drug development company formed to bring commercial value to the pioneering work of Prof Barry V. L. Potter (University of Oxford) in the design and development of small molecule targeted therapeutics in the fields of hormone-dependent and hormone independent cancer.

With Dr John R. Normanton, the Company’s founding CEO, they are exploiting over 25 years experience of working together in taking ground-breaking steroidal and steroidally-inspired candidates from bench to bedside.